Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Peposertib||M3814|M-3814|Nedisertib|MSC2490484A||DNA_PK Inhibitor 7||Peposertib (MSC2490484A) is a DNA-dependent protein kinase (DNA-PK) inhibitor that blocks DNA damage repair, which may lead to antitumor activity by sensitizing cancer cells to radiation and agents that induce DNA double strand breaks (PMID: 32220971).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04172532||Phase Ib/II||Peposertib||Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer||Suspended||USA||0|
|NCT02516813||Phase I||Peposertib||Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy||Completed||USA | DEU | BEL||5|
|NCT03116971||Phase Ib/II||Cisplatin + Etoposide + Peposertib Peposertib||Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)||Terminated||USA | ITA | ESP | DEU | CAN | BEL||7|
|NCT04555577||Phase I||Peposertib Temozolomide||Nedisertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma||Recruiting||USA||0|
|NCT04533750||Phase I||Peposertib||Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin||Recruiting||USA||0|